Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement

被引:13
作者
Baeumler, Joerg [2 ]
Szuhai, Karoly [3 ]
Falkenburg, J. H. Frederik [1 ]
van Schie, Marianke L. J. [1 ]
Ottmann, Oliver G. [2 ]
Nijmeijer, Bart A. [1 ]
机构
[1] Leiden Univ, Med Ctr C2R, Dept Hematol, NL-2300 RC Leiden, Netherlands
[2] Goethe Univ Frankfurt, Dept Hematol, Frankfurt, Germany
[3] Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1016/j.cancergencyto.2008.05.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fusion kinases (FK) like BCR/ABL1 mediate leukemic transformation and represent therapeutic targets. Fusion of ETV6 (ETS translocation variant 6, previously known as TEL) to ABL1 due to t(9; 12) has been observed in various hematological malignancies. ETV6/ABL1 and BCR/ABL1 FK display similar activity but they may not be identical in function. Here we present the generation of an ETV6/ABL1 positive human acute lymphoblastic leukemia (ALL) cell line, ALL-VG. The cell line expressed ETV6/ABL1 fusion transcripts and displayed sensitivity to imatinib with an IC50 of 0.1 mu M. Karyotyping did not reveal overt t(9; 12), suggesting a cryptic translocation. Fluorescent in situ hybridization and array-based comparative genomic hybridization were performed to characterize the rearrangement. ETV6/ABL1 fusion was demonstrated to result from insertion of a duplicated 300 to 1300 kb region of 9q34 that contained the distal portion of the ABL1 gene, into the ETV6 locus on 12p13. With this insertion, an 1150 to 1750 kb region of 12p13 that contained the distal portion of the ETV6 gene as well the cyclin dependent kinase inhibitor (CDKN) 1B gene was lost. Furthermore, the cells displayed a del(9)(p21.1 similar to p23), typically associated with loss of CDKN2A and CDKN2B. The ALL-VG cell line may serve as a tool for the study of ETV6/ABL1. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:37 / 42
页数:6
相关论文
共 34 条
[1]  
Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299
[2]   The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A [J].
Chakrabarti, SR ;
Nucifora, G .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 264 (03) :871-877
[3]   Tyrosine kinase fusion genes in chronic myeloproliferative diseases [J].
Cross, NCP ;
Reiter, A .
LEUKEMIA, 2002, 16 (07) :1207-1212
[4]   The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].
Deininger, M ;
Buchdunger, E ;
Druker, BJ .
BLOOD, 2005, 105 (07) :2640-2653
[5]  
Drexler HG, 1999, LEUKEMIA RES, V23, P207
[6]   FUSION OF PDGF RECEPTOR-BETA TO A NOVEL ETS-LIKE GENE, TEL, IN CHRONIC MYELOMONOCYTIC LEUKEMIA WITH T(512) CHROMOSOMAL TRANSLOCATION [J].
GOLUB, TR ;
BARKER, GF ;
LOVETT, M ;
GILLILAND, DG .
CELL, 1994, 77 (02) :307-316
[7]  
Golub TR, 1996, MOL CELL BIOL, V16, P4107
[8]   Colony growth of human hematopoietic progenitor cells in the absence of serum is supported by a proteinase inhibitor identified as antileukoproteinase [J].
Goselink, HM ;
vanDamme, J ;
Hiemstra, PS ;
Wuyts, A ;
Stolk, J ;
Fibbe, WE ;
Willemze, R ;
Falkenburg, JHF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (04) :1305-1312
[9]   Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line [J].
Griesinger, F ;
Janke, A ;
Podleschny, M ;
Bohlander, SK .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) :454-458
[10]   TEL/AML1 shows dominant-negative effects over TEL as well as AML1 [J].
Gunji, H ;
Waga, K ;
Nakamura, F ;
Maki, K ;
Sasaki, K ;
Nakamura, Y ;
Mitani, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 322 (02) :623-630